Kathryn Claborn, APRN
Family · Ruston, LANPI 1295220549
Payments from drug & device makers
Across 406 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Bayer$1K
- Lilly USA, LLC$981
- Dexcom, Inc.$485
- Abbott$435
- BETA Bionics, Inc.$346
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,12099%
- Education$70%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,735 |
| Bayer | 62 | $1,035 |
| Lilly USA, LLC | 55 | $981 |
| Dexcom, Inc. | 25 | $485 |
| Abbott | 27 | $435 |
| BETA Bionics, Inc. | 21 | $346 |
| Insulet Corporation | 16 | $298 |
| Corcept Therapeutics | 15 | $257 |
| Averitas Pharma Inc. | 12 | $219 |
| AstraZeneca | 2 | $166 |
| Esperion Therapeutics, Inc. | 11 | $164 |
| Kowa Pharmaceuticals America, Inc. | 7 | $130 |
| Boehringer Ingelheim | 8 | $118 |
| Sanofi-aventis U.S. LLC | 8 | $118 |
| Medtronic | 6 | $117 |
| Xeris Pharmaceuticals, Inc. | 5 | $79 |
| Amgen | 4 | $74 |
| Mannkind Corporation | 1 | $59 |
| Tandem Diabetes Care, Inc. | 3 | $53 |
| Cequr Corporation | 1 | $39 |
| Novartis | 2 | $39 |
| Sequel Med Tech, LLC | 2 | $37 |
| Nevro Corp. | 2 | $36 |
| Evoke Pharma, Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Merck | 2 | $30 |
| Global Blood Therapeutics, Inc. | 1 | $25 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,186 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 335 | $346,063 |
| OzempicSemaglutide | 296 | $322,735 |
| FarxigaDapagliflozin Propanediol | 231 | $143,064 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 136 | $120,352 |
| JardianceEmpagliflozin | 133 | $100,338 |
| TrulicityDulaglutide | 85 | $91,669 |
| Tresiba Flextouch U-200Insulin Degludec | 72 | $58,738 |
| RybelsusSemaglutide | 45 | $50,229 |
| Humalog Kwikpen U-200Insulin Lispro | 28 | $49,776 |
| GlyxambiEmpagliflozin/Linagliptin | 68 | $46,771 |
| KerendiaFinerenone | 60 | $43,069 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 68 | $41,152 |
| Tresiba Flextouch U-100Insulin Degludec | 65 | $36,939 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $24,289 |
| Xigduo XrDapaglifloz Propaned/Metformin | 25 | $24,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $981 | $445,302441 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Novolog | $1,735 | $415,215412 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr | $118 | $157,875216 claims |
| AstraZenecaFarxiga | $166 | $143,064231 claims |
| BayerKerendia | $1,035 | $43,06960 claims |
| MerckJanumet Xr, Januvia | $30 | $22,44530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Ruston
- Ashlea HillRuston$169K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.